Approval of proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies (mAbs), such as daratumumab and isatuximab, have reshaped MM treatment in Japan and these have been defined by the Japanese Society of Hematology (JSH) as ‘key drugs’ [4–6]. The gene discussed is CD38; the disease is Miyoshi myopathy.